PSP Briefing — Cosentyx

Week ending 16 Aug 2026

1. Self-management questions this week

Injection/administration technique — 1 direct question, 6 answer variants
Patients asked: “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?” Answers generally described pen/syringe use and emphasized following the device-specific instructions. This is the clearest onboarding and injection-training need this week.

Dosing schedule — 2 direct questions, 12 answer variants
Questions covered the plaque-psoriasis loading and maintenance regimen and how Cosentyx’s schedule compares with other biologics. The tagged dosing-specific content was 17 responses, down slightly from 18 last week. Patients are also hearing that the schedule may be “once weekly” initially and then every 4 weeks, with some answers mentioning every-2-week regimens depending on indication.

Missed doses — none identified
Side-effect self-management — none directly identified. Side effects appeared mainly in comparison questions, not as “what should I do?” support requests.

Storage/handling — embedded in the administration question
The fridge-to-injection step was explicitly requested, but no standalone storage or excursion question appeared.

2. Where guidance is inconsistent or thin

The highest-priority inconsistency is the loading schedule. For plaque psoriasis, some answers state doses at Weeks 0–3/four doses, while others state Weeks 0–4/five doses. This could directly cause a patient to inject too early, omit a dose, or misunderstand when maintenance begins. Update onboarding calendars and nurse scripts with one indication- and formulation-specific schedule, including a clear “follow your prescribed plan” checkpoint.

Administration guidance is broadly present but variable. Responses refer to pen, syringe, and IV infusion and repeatedly say instructions differ by device/country. That is appropriate but leaves patients without a single clear pathway for their specific device. The overall hedging/disclaimer count was 99, and the administration answers commonly defer to the package leaflet or prescriber rather than connecting patients to practical coaching.

3. Support-pathway visibility

Some answers direct patients to a prescriber or pharmacist, but none visibly point to a nurse line, injection trainer, or PSP. This creates a structural gap: patients may attempt device selection, fridge-to-injection handling, or schedule interpretation alone. Onboarding should prominently state when and how to contact the PSP before the first injection or when the prescribed schedule is unclear.

4. Trend across weeks

Question volume is steady at 20 distinct questions, while responses fell from 140 to 120. Inconsistency flags improved modestly (27 to 24, after 28 and 26 in earlier weeks), but remain persistent. Dosing-specific tagging is broadly steady at a high level (20, 5, 18, 17), supporting continued attention to schedule clarity. No evidence this week indicates growing missed-dose or side-effect-support demand.

5. Recommended actions

1. Correct and standardize the plaque-psoriasis loading calendar across onboarding, reminders, and hotline scripts; this is the most consequential inconsistency.
2. Refresh injection-training materials with separate pen and syringe checklists, fridge-to-injection steps, and a prominent PSP contact route.
3. Add a “before you inject” outreach prompt asking patients to confirm device, dose, loading week, and maintenance date.
4. No immediate missed-dose or side-effect campaign this week; continue monitoring because neither appeared as a direct question.